Earlier this week, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA trial dosimetry results for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in key ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology 1, demonstrating that ...

Learn more Those following along with Telix Pharmaceuticals Limited (ASX:TLX) will no doubt be intrigued by the recent purchase of shares by Christian Behrenbruch, Co-Founder of the company, who spent ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18 F]fluoroethyl)-L-tyrosine, 18 ...

Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase ...

Professor Emmett will showcase data from her OPTIMAL-PSMA 2 investigator-initiated trial of TLX597-Tx ( 177 Lu-DOTA-PSMA), Telix’s novel second generation small molecule candidate being developed to ...

The ASX biotech stock offers high-growth potential, but it comes with volatility. The post What's driving the wild swings in ...

MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a ...

Investors celebrating the summer resurgence of biotech IPOs might want to put the champagne back on ice, after Telix Pharmaceuticals made the last-minute decision to pull its own Nasdaq listing. The ...

Dr. Clint Bahler, an Indiana University Health urologist, reviews scans of cancer patients that are more readable thanks to an imaging agent called Illuccix. (Photo courtesy of Telix) Larry Doone ...

Telix Pharmaceuticals Limited (NASDAQ:TLX) on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), ...